Stock Price
54.27
Daily Change
-1.88 -3.35%
Monthly
19.59%
Yearly
-58.61%
Q3 Forecast
54.42

Novo Nordisk reported DKK16.11B in Selling and Administration Expenses for its fiscal quarter ending in March of 2025.


Selling And Administration Expenses Change Date
ANI Pharmaceuticals USD 81.77M 5.24M Jun/2025
Aurora Cannabis CAD 45.63M 7.45M Jun/2025
Bausch Health Companies USD 894M 27M Jun/2025
Bristol-Myers Squibb USD 1.71B 129M Jun/2025
Canopy Growth CAD 40.12M 504K Jun/2025
Corcept Therapeutics USD 103.85M 13.19M Jun/2025
Drreddys Laboratories INR 23.18B 1.59B Jun/2025
Eli Lilly USD 2.75B 390.8M Jun/2025
GlaxoSmithKline GBP 2.14B 80M Jun/2025
Merck USD 2.63B 104M Jun/2025
Novartis USD 3.44B 384M Jun/2025
Novo Nordisk 18.85B 2.74B Jun/2025
Novo Nordisk DKK 16.11B 480M Mar/2025
Pacira USD 77.19M 9.58M Jun/2025
Perrigo USD 273.1M 8.1M Jun/2025
Prestige Brands USD 28.46M 35.6M Jun/2025
Sanofi EUR 2.63B 408M Jun/2025
Supernus Pharmaceuticals USD 62.22M 27.72M Jun/2025
Zoetis USD 617M 54M Jun/2025